16-3729447-C-T
Variant summary
Our verdict is Pathogenic. The variant received 16 ACMG points: 16P and 0B. PM1PM2PM5PP3_ModeratePP5_Very_Strong
The NM_004380.3(CREBBP):c.5600G>A(p.Arg1867Gln) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R1867W) has been classified as Pathogenic.
Frequency
Consequence
NM_004380.3 missense
Scores
Clinical Significance
Conservation
Publications
- Rubinstein-Taybi syndromeInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen, Illumina
- Rubinstein-Taybi syndrome due to CREBBP mutationsInheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, G2P
- Menke-Hennekam syndrome 1Inheritance: AD Classification: STRONG Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 16 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| CREBBP | NM_004380.3 | c.5600G>A | p.Arg1867Gln | missense_variant | Exon 31 of 31 | ENST00000262367.10 | NP_004371.2 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 35
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Menke-Hennekam syndrome 1 Pathogenic:3Uncertain:1
- -
ACMG Criteria: PP3, PP5, PM1, PM2_P, PM5; Variant was found in heterozygous state. -
- -
- -
Rubinstein-Taybi syndrome Pathogenic:1
In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the p.Arg1867 amino acid residue in CREBBP. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 27311832). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CREBBP protein function. ClinVar contains an entry for this variant (Variation ID: 429336). This missense change has been observed in individual(s) with clinical features of CREBBP-related conditions (PMID: 27311832, 29460469). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 1867 of the CREBBP protein (p.Arg1867Gln). -
not provided Pathogenic:1
In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 27311832, 29460469, 35904121, 35982159, 35626936, 33057194, 37025449) -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at